M7920
Minoxidil Sulfate
K+ channel opener, powder
Synonym(s):
U-58838
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C9H15N5O4S
CAS Number:
Molecular Weight:
289.31
UNSPSC Code:
12352107
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Form:
powder
Quality level:
Product Name
Minoxidil Sulfate,
SMILES string
Nc1cc(nc(N)[n+]1OS([O-])(=O)=O)N2CCCCC2
InChI
1S/C9H15N5O4S/c10-7-6-8(13-4-2-1-3-5-13)12-9(11)14(7)18-19(15,16)17/h6H,1-5H2,(H4,10,11,12,15,16,17)
InChI key
OEOLOEUAGSPDLT-UHFFFAOYSA-N
form
powder
originator
Johnson & Johnson
storage temp.
−20°C
Quality Level
Looking for similar products? Visit Product Comparison Guide
Related Categories
Application
Minoxidil sulfate (MXS) has been used as a drug agent to study its effects on alopecia in corticotropin-releasing factor over-expressing (CRF-OE) mice. It has also been used as a positive control in an assay for the culturing of rat vibrissa follicles.
Biochem/physiol Actions
Minoxidil sulfate (MXS) is an endogenous derivative of minoxidil. It possesses greater aqueous solubility and is a potent vasodilator. MXS has the potential to treat androgenic alopecia or male baldness.
Features and Benefits
This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Other Notes
Active metabolite of minoxidil.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
Storage Class
11 - Combustible Solids
wgk
WGK 3
ppe
dust mask type N95 (US), Eyeshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
K S Atwal
Journal of cardiovascular pharmacology, 24 Suppl 4, S12-S17 (1994-01-01)
KATP openers are recognized as having a therapeutic potential for the treatment of various cardiovascular and noncardiovascular diseases. However, the first-generation agents open KATP in a variety of tissues that limit their potential clinical utility. This review describes our studies
C E Ohrnberger et al.
The Journal of pharmacology and experimental therapeutics, 267(1), 25-30 (1993-10-01)
Glyburide, a sulfonylurea, and U-37883A, a guanidine (4-Morpholinecarboximidine-N-1-Adamantyl-N' cyclohexylhydrochloride), have been previously characterized as antagonists of the vascular ATP-sensitive K+ channels (KATP). In this report, the in vitro interaction between these two chemically distinct KATP antagonists was investigated using isolated
K Bray et al.
Naunyn-Schmiedeberg's archives of pharmacology, 345(2), 244-250 (1992-02-01)
The effects of the K+ channel blockers tedisamil and glibenclamide on cromakalim- and minoxidil sulphate-induced 42K+ and 86Rb+ efflux and vasorelaxation in rat aorta, were investigated. In aortic strips preloaded with 42K+ or 86Rb+, cromakalim (1 mumol/l) induced increases in
K M Bray et al.
The Journal of biological chemistry, 267(17), 11689-11692 (1992-06-15)
The K+ channel openers, including cromakalim, pinacidil, minoxidil sulfate, diazoxide, and nicorandil, form a chemically heterogeneous group of compounds, which relax smooth muscle by opening plasmalemmal K+ channels. At present it is not known whether these drugs elicit their effects
Nagendra S Ningaraj et al.
Cancer research, 63(24), 8899-8911 (2003-12-26)
Brain tumor microvessels/capillaries limit drug delivery to tumors by forming a blood-brain tumor barrier (BTB). The BTB overexpresses ATP-sensitive potassium (K(ATP)) channels that are barely detectable in normal brain capillaries, and which were targeted for BTB permeability modulation. In a
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service